Cardiac Science Reports Q2 Revenue; Resumes AED...(5154 9.9% Stock-based com...),Health

Date:8/10/2009

5,154 9.9% Stock-based compensation 554 1.5% 488 0.9% Adjusted EBITDA $(1,223) -3.4% $5,642 10.8% ======= ==== ====== ==== Reconciliation of Net Income (Loss) Attributable to Cardiac Science Corporation to Adjusted EBITDA Six Months Ended Six Months Ended June 30, 2009 June 30, 2008 ------------- ------------- % of % of revenue revenue -------- ------- Net income (loss) attributable to Cardiac Science Corporation $(2,644) -3.5% $4,340 4.3% Depreciation and amortization 3,067 4.0% 3,233 3.2% Interest income (32) 0.0% (278) -0.3% Income tax (benefit) expense (1,360) -1.8% 2,647 2.6% ------ ---- ----- --- EBITDA (969) -1.3% 9,942 9.8% Stock-based compensation 1,213 1.6% 1,046 1.0% Adjusted EBITDA $244 0.3% $10,988 10.9% ==== === ======= ==== CSCX-F

'/>"/>

SOURCE Cardiac Science Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine news :

1. Electronic Health Records Help Cardiac Patients Remain Healthy
2. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
3. Harrison City ROCKS! Set for August 15, Music Festival to Benefit Cardiac Research at Childrens Hospital of Pittsburgh
4. Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent(TM) Portfolio License
5. Many Heart Attack Patients Not Referred to Cardiac Rehab
6. Worlds First Cardiac Adult Stem Cell Patient and Physicians Discuss Clinical Trial
7. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
8. Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths
9. Cardiac CT is more cost effective when managing low-risk patients with chest pain
10. Improving Care for Cardiac Patients is Centerpiece of American Society of Nuclear Cardiology Meeting
11. ERT Launches New Online Gateway to Improve Cardiac Safety in Clinical Trials